The FDA reversed its decision and will now review Moderna's application for an mRNA flu vaccine for adults 50 and older, following industry backlash over a previous rejection due to clinical trial design disputes; this matters as it impacts vaccine development timelines and regulatory trust. At a PhRMA forum, differing tones were struck by top U.S. health officials regarding the relationship between government and pharmaceutical industries, highlighting internal divisions that content creators should monitor for potential policy shifts affecting public health messaging.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



